CLONING AND PROMOTER ANALYSIS OF HUMAN CHOLINE KINASE ISOFORMS

YEE YOKE HIANG

UNIVERSITI SAINS MALAYSIA

2012
CLONING AND PROMOTER ANALYSIS OF
HUMAN CHOLINE KINASE ISOFORMS

BY

YEE YOKE HIANG

Thesis submitted in fulfillment of the requirements
for the degree of
Master of Science

September 2012
ACKNOWLEDGEMENTS

First of all, I would like to thank my supervisors, Dr. See Too Wei Cun and Dr. Few Ling Ling for their trust in giving me a chance to complete my study in the Master of Science. They gave me scientific guidance and advice, assisted me in solving problems and encouraged my research progress. I am also very appreciative of their help throughout the preparation of this thesis.

I would also like to extend my sincere appreciation to Dr. Yvonne Tee Get Bee for her willingness to be my co-supervisor and for her invaluable help in this research study especially in the area of data analysis. In addition, I would also like to express my gratitude to Dr. Khoo Boon Yin for kindly providing me with the human breast adenocarcinoma, MCF-7 cells and human hepatoma, HepG2 cells.

I would like to record special thanks to the officers and technologists from the School of Health Sciences. They gave me assistance in the form of technical advice and guidance to my whole study.

I am very thankful to Universiti Sains Malaysia for its generous financial support in the form of the USM Fellowship and Research University Grant Scheme (1001/PPSK/813034) and in all aspects of my Master of Science research.

Finally, I would like extend my gratitude to all my laboratory members for their friendship that enlightened my laboratory life making it so special and memorable.
With their co-operation, moral support and the sharing of ideas, my MSc. study was completed smoothly.

Last but not least, I would like to appreciate my family and my husband for their continuous support and love.
# TABLE OF CONTENTS

ACKNOWLEDGEMENTS ........................................................................................................ ii

TABLE OF CONTENTS ........................................................................................................ iv

LIST OF TABLES ................................................................................................................ viii

LIST OF FIGURES ................................................................................................................ ix

LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMNS ........................................... xi

ABSTRAK ............................................................................................................................ xv

ABSTRACT .......................................................................................................................... xvii

CHAPTER 1.0 INTRODUCTION ......................................................................................... 1

1.1 Structures and functions of phospholipids ............................................................... 1

1.1.1 Phosphoglycerides ............................................................................................... 1

1.1.1(a) Phosphatidic acid ......................................................................................... 3

1.1.1(b) Phosphatidylcholine .................................................................................... 5

1.1.1(c) Phosphatidylethanolamine ........................................................................ 5

1.1.1(d) Phosphatidylserine ...................................................................................... 6

1.1.1(e) Phosphatidylglycerol .................................................................................... 6

1.1.1(f) Diphosphatidylglycerol ............................................................................... 7

1.1.1(g) Phosphatidylinositol ................................................................................... 7

1.1.2 Sphingolipids .................................................................................................... 8

1.2 Biosynthesis of major phospholipids in eukaryotic membranes ........................... 10

1.2.1 Synthesis of phosphatidic acid ...................................................................... 12

1.2.2 Synthesis of phosphatidylcholine .................................................................. 12

1.2.2(a) CDP-choline pathway ............................................................................... 13

1.2.2(b) Phosphatidylethanolamine methylation pathway ................................... 14

1.2.3 Synthesis of phosphatidylethanolamine ....................................................... 14

1.2.4 Synthesis of phosphatidylserine ................................................................. 15

1.3 Choline kinase ........................................................................................................ 16

1.3.1 Biochemical characteristic of choline kinase isoforms ................................ 17

1.4 Choline kinase in cell transformation and carcinogenesis ................................ 19

1.5 Promoter .................................................................................................................. 22

1.5.1 Transcription factors ...................................................................................... 22

1.5.2 Transcriptional regulation of choline kinase ............................................... 25

1.6 Statement of problem and rationale of study ....................................................... 31
1.7 Aims of the study........................................................................................................... 32

CHAPTER 2.0 MATERIALS AND METHODS......................................................... 35

2.1 Materials ....................................................................................................................... 35
2.1.1 Chemicals and reagents ......................................................................................... 35
2.1.2 Enzymes .................................................................................................................. 35
2.1.3 Kits ............................................................................................................................. 35
2.1.4 Consumables............................................................................................................. 35
2.1.5 General instruments .............................................................................................. 35

2.2 Methods....................................................................................................................... 43
2.2.1 Sterilization of buffers and consumables ............................................................... 43
2.2.2 Maintenance of Escherichia coli cell ................................................................. 43
    2.2.2(a) Preparation of bacterial culture medium..................................................... 43
        2.2.2(ai) LB (Luria-Bertani) medium ................................................................. 43
        2.2.2(aii) LB agar with ampicillin plates ......................................................... 44
        2.2.2(aiii) Medium A ....................................................................................... 44
        2.2.2(aiv) Medium B ....................................................................................... 44
    2.2.2(b) Preparation of E. coli glycerol stock ........................................................... 44
    2.2.2(c) Preparation of XL1-Blue competent cells ............................................... 45

2.2.3 Culture of human cancer cell lines ................................................................. 45
    2.2.3(a) Preparation of medium and buffers.......................................................... 46
        2.2.3(ai) Cell culture medium ......................................................................... 46
        2.2.3(aii) Heat inactivation of fetal bovine serum ........................................... 46
        2.2.3(aiii) Preparation of Phosphate buffered saline ........................................ 46
        2.2.3(aiv) Trypsin-EDTA .............................................................................. 47
        2.2.3(av) Cryopreservation medium .............................................................. 47
    2.2.3(b) Cell passage of human cancer cell lines .................................................. 47
    2.2.3(c) Cryopreservation of human cancer cell lines ......................................... 47
    2.2.3(d) Revival of cryopreserved human cancer cell lines ............................... 48
    2.2.3(e) Cell counting ......................................................................................... 48

2.2.4 Software for promoter analysis and other bioinformatics analysis .... 51
2.2.5 Polymerase chain reaction (PCR)................................................................. 51
    2.2.5(a) PCR primers ......................................................................................... 51
    2.2.5(b) Oligonucleotides preparation .............................................................. 55
    2.2.5(c) Human genomic DNA ........................................................................ 55
2.2.5(d) DNA sequencing ................................................................. 55
2.2.6 Plasmid for cloning of *ckα* and *ckβ* promoters .................. 55
2.2.7 Plasmid extraction ............................................................... 55
2.2.8 Agarose gel electrophoresis .................................................. 56
2.2.8(a) Preparation of 1% agarose gel ..................................... 60
2.2.8(b) Tris-acetate-EDTA buffer (10X) ................................. 60
2.2.8(c) 6X DNA loading dye ....................................................... 60
2.2.8(d) 2X RNA loading dye ....................................................... 60
2.2.8(e) Sample preparation for the electrophoresis ................. 60
2.2.8(f) Ethidium bromide (EtBr) DNA staining solution ............. 60
2.2.9 DNA gel extraction .............................................................. 60
2.2.10 Determination of DNA and RNA concentration ............... 61
2.2.11 DNA digestion with restriction endonucleases ................ 61
2.2.12 Purification of restriction enzyme digested DNA .......... 61
2.2.13 DNA ligation ................................................................. 61
2.2.14 Heat-shock transformation of *E. coli* competent cells .... 61
2.2.15 Determination of transcriptional start site ..................... 61
2.2.15(a) Total RNA extraction .................................................. 61
2.2.15(b) 5’ RLM-RACE ......................................................... 61
2.2.16 Identification of transcription factor binding element .... 61
2.2.17 Transient transfection of MCF-7 cells .............................. 61
2.2.18 Dual-Glo luciferase assay ............................................... 61
2.2.19 Site directed mutagenesis by PCR ................................. 61
2.2.20 Treatment of MCF-7 cells with Phorbol-12-Myristate-13-Acetate (PMA) ................................................................. 61
2.2.21 Statistical analysis ........................................................ 61

CHAPTER 3.0 RESULTS ........................................................................ 77
3.1 Cloning of *ckα* and *ckβ* promoters ............................... 77
3.2 Determination of transcriptional start site for *ckα* and *ckβ* promoters ...................... 77
3.3 Identification of transcription factor binding elements of *ckα* and *ckβ* promoters ................................................................. 77
3.4 Construction of *ckα* promoter ............................................ 77
3.5 Construction of *ckβ* promoter ............................................ 77
3.6 Optimization of transient transfection ................................ 77
3.7 Identification of highly functional regulatory regions of ckα promoter .... 101
3.8 Identification of highly functional regulatory regions of ckβ promoter .... 106
3.9 Effect of ETS and GATA sites mutations on ckβ promoter activity .... 109
3.10 Effect of PMA treatment on ckβ promoter ........................................ 111

CHAPTER 4.0 DISCUSSION................................................................................. 113
4.1 Cloning of ckα and ckβ promoters ......................................................... 113
4.2 Transcriptional start site determination .................................................. 114
4.3 Determination of transcription factor binding sites ................................... 117
4.4 Gene reporter assays ............................................................................. 118
4.5 Transcription factors that are involved in the regulation of ckα and ckβ gene expression ................................................................. 122
4.6 ETS transcription factor negatively regulates the ckα gene expression.... 123
4.7 ETS and GATA transcription factors negatively regulates the ckβ gene expression ................................................................. 126

CHAPTER 5.0 CONCLUSION.............................................................................. 131
REFERENCES................................................................................................. 135
APPENDICES .................................................................................................. 161
LIST OF PUBLICATIONS................................................................................. 174
LIST OF TABLES

Table 1.1  Major types of phosphoglycerides ......................................................... 4
Table 1.2  Some major transcription factor families and functions ...................... 24
Table 2.1  List of chemicals and reagents ............................................................... 36
Table 2.2  List of enzymes ..................................................................................... 38
Table 2.3  List of kits ............................................................................................... 39
Table 2.4  List of consumables ............................................................................... 40
Table 2.5  List of general instruments .................................................................... 41
Table 2.6  Software for promoter analysis and other bioinformatics analysis .... 52
Table 2.7  PCR primers .......................................................................................... 53
Table 2.8  Plasmid constructs of $cka$ and $ckb$ promoters produced in this study. ........................................................................................................ 59
# LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>The structure of plasma membrane.</td>
</tr>
<tr>
<td>1.2</td>
<td>Core structure of sphingolipids, long chain bases form the core structure of sphingolipids</td>
</tr>
<tr>
<td>1.3</td>
<td>Pathways for the biosynthesis of major eukaryotic membrane phospholipids</td>
</tr>
<tr>
<td>1.4</td>
<td>The possible regulatory elements for mouse cka and ckb genes</td>
</tr>
<tr>
<td>1.5</td>
<td>Schematic diagram of the putative HRE binding sites in human cka promoter</td>
</tr>
<tr>
<td>1.6</td>
<td>Flow chart of study</td>
</tr>
<tr>
<td>2.1</td>
<td>Schematic diagram of Haemocytometer and cells counting system</td>
</tr>
<tr>
<td>2.2</td>
<td>Map for the pGL4.10[luc2] vector</td>
</tr>
<tr>
<td>2.3</td>
<td>Map for the pGL4.73[hRLuc/SV40] vector</td>
</tr>
<tr>
<td>2.4</td>
<td>Schematic diagram of 5’ RLM-RACE procedure</td>
</tr>
<tr>
<td>2.5</td>
<td>Schematic diagram of Dual-Glo reporter assay system</td>
</tr>
<tr>
<td>3.1</td>
<td>Promoter sequences of cka</td>
</tr>
<tr>
<td>3.2</td>
<td>Promoter sequences of ckb</td>
</tr>
<tr>
<td>3.3</td>
<td>PCR amplified cka and ckb promoters</td>
</tr>
<tr>
<td>3.4</td>
<td>Restriction digestion analysis of cka and ckb promoters</td>
</tr>
<tr>
<td>3.5</td>
<td>Total RNA extracted from the human liver hepatocellular carcinoma</td>
</tr>
<tr>
<td>3.6</td>
<td>PCR products of TSS cka and ckb promoters</td>
</tr>
<tr>
<td>3.7</td>
<td>The DNA sequence alignment result of TSS for cka and ckb promoters</td>
</tr>
<tr>
<td>3.8</td>
<td>The potential transcription factor binding sites of cka promoter</td>
</tr>
<tr>
<td>3.9</td>
<td>The potential transcription factor binding sites of ckb promoter</td>
</tr>
<tr>
<td>3.10</td>
<td>Double restriction enzymes analysis of cka deletion constructs</td>
</tr>
<tr>
<td>3.11</td>
<td>PCR products of second and third series of cka deletion constructs</td>
</tr>
<tr>
<td>3.12</td>
<td>Double digestion analysis of second and third series of cka deletion constructs</td>
</tr>
<tr>
<td>3.13</td>
<td>PCR products of ckb deletion constructs</td>
</tr>
<tr>
<td>3.14</td>
<td>Double digestion analysis of ckb deletion constructs</td>
</tr>
<tr>
<td>3.15</td>
<td>Effect of varying concentrations of internal control (Renilla luciferase) vector on test reporter (firefly luciferase) activity</td>
</tr>
<tr>
<td>3.16</td>
<td>Deletion constructs of cka promoter</td>
</tr>
<tr>
<td>3.17</td>
<td>Second series deletion constructs of cka promoter</td>
</tr>
</tbody>
</table>
Figure 3.18  Third series deletion constructs of cka promoter. .......................... 105
Figure 3.19  Deletion constructs of ckβ promoter........................................... 107
Figure 3.20  Second series deletion constructs of ckβ promoter.......................... 108
Figure 3.21  Luciferase activity of full length and mutant ckβ promoter constructs................................................................. 110
Figure 3.22  The effect of PMA treatment on full length and mutant ckβ promoter constructs. .................................................. 112
Figure 4.1  The suggested regulation pathway of ckβ promoter by ETS and GATA transcription factors........................................ 130
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>~</td>
<td>Approximately</td>
</tr>
<tr>
<td>%</td>
<td>Percentage</td>
</tr>
<tr>
<td>°C</td>
<td>Degree Celsius</td>
</tr>
<tr>
<td>μg</td>
<td>Microgram</td>
</tr>
<tr>
<td>μl</td>
<td>Microliter</td>
</tr>
<tr>
<td>μM</td>
<td>Micromolar</td>
</tr>
<tr>
<td>AhR/Ar</td>
<td>Aryl hydrocarbon receptor/androgen receptor</td>
</tr>
<tr>
<td>AP-1</td>
<td>Activator protein 1</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine-5’-triphosphate</td>
</tr>
<tr>
<td>bp</td>
<td>Base pair</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>CCl₄</td>
<td>Carbon tetrachloride</td>
</tr>
<tr>
<td>cDNA</td>
<td>Complementary DNA</td>
</tr>
<tr>
<td>CL</td>
<td>Cardiolipin</td>
</tr>
<tr>
<td>CREB</td>
<td>cAMP responsive element binding</td>
</tr>
<tr>
<td>cm</td>
<td>Centimeter</td>
</tr>
<tr>
<td>DBTSS</td>
<td>Database of transcriptional start sites</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s modified Eagle’s medium</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethylsulfoxide</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>DNTP</td>
<td>Deoxyribonucleotide triphosphate</td>
</tr>
<tr>
<td>E2F</td>
<td>Electro-acoustic 2 factor</td>
</tr>
<tr>
<td><em>E. coli</em></td>
<td><em>Escherichia coli</em></td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>EGF</td>
<td>Epidermal growth factor</td>
</tr>
<tr>
<td>EK</td>
<td>Ethanolamine kinase</td>
</tr>
<tr>
<td>Elk</td>
<td>E-twenty six-like</td>
</tr>
<tr>
<td>ER</td>
<td>Endoplasmic reticulum</td>
</tr>
<tr>
<td>EtBr</td>
<td>Ethidium bromide</td>
</tr>
</tbody>
</table>
ETS E-twenty six
FBS Fetal bovine serum
g/l Gram per liter
g Gram
H₂O Water
cₐ Choline kinase alpha
c₇β Choline kinase beta
HepG2 Human liver hepatocellular carcinoma
HRG Heregulin
HSF Heat shock factor
Ik Ikaros
IPTG Isopropyl-β-D-thiogalactopyranoside
kb Kilobase
kDa Kilo Dalton
L Liter
LB Luria-Bertani
Lyf-1 Lymphoid transcription factor 1
luc2 Luciferase
MCF-7 Human breast adenocarcinoma
mg Milligram
ml Milliliter
mm Millimeter
mM Millimolar
mRNA Messenger RNA
MZF1 Myeloid zinc finger 1
NCBI National Center for Biotechnology Information
NF-kappa Nuclear factor kappa
ng Nanogram
nm Nanometer
p300 Protein 300
PA Phosphatidic acid
PAH Polycyclic aromatic hydrocarbon
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PC</td>
<td>Phosphatidylcholine</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PDGF</td>
<td>Platelet-derived growth factor</td>
</tr>
<tr>
<td>PE</td>
<td>Phosphatidylethanolamine</td>
</tr>
<tr>
<td>PG</td>
<td>Phosphatidylglycerol</td>
</tr>
<tr>
<td>PI</td>
<td>Phosphatidylinositol</td>
</tr>
<tr>
<td>PKC</td>
<td>Protein kinase C</td>
</tr>
<tr>
<td>PMA</td>
<td>Phorbol-12-Myristate-13-Acetate</td>
</tr>
<tr>
<td>PS</td>
<td>Phosphatidylserine</td>
</tr>
<tr>
<td>psi</td>
<td>Pound-force per square inch</td>
</tr>
<tr>
<td>RLM-RACE</td>
<td>RNA Ligase Mediated Rapid Amplification of cDNA Ends</td>
</tr>
<tr>
<td>Rluc</td>
<td><em>Renilla</em> luciferase</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>rpm</td>
<td>Revolutions per minute</td>
</tr>
<tr>
<td>rRNA</td>
<td>Ribosomal RNA</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>SM</td>
<td>Sphingomyelin</td>
</tr>
<tr>
<td>Sp1</td>
<td>Specificity protein 1</td>
</tr>
<tr>
<td>SRY</td>
<td>Sex-determining region Y</td>
</tr>
<tr>
<td>SV40</td>
<td>Simian virus 40</td>
</tr>
<tr>
<td>TAE</td>
<td>Tris-acetate-EDTA</td>
</tr>
<tr>
<td>TE</td>
<td>Tris-EDTA</td>
</tr>
<tr>
<td>TFSEARCH</td>
<td>Searching transcription factor binding sites</td>
</tr>
<tr>
<td>T&lt;sub&gt;m&lt;/sub&gt;</td>
<td>Melting temperature</td>
</tr>
<tr>
<td>Tris</td>
<td>Tris(hydroxymethyl)-aminomethane</td>
</tr>
<tr>
<td>tRNA</td>
<td>Transfer RNA</td>
</tr>
<tr>
<td>TSS</td>
<td>Transcriptional start site</td>
</tr>
<tr>
<td>U</td>
<td>Unit</td>
</tr>
<tr>
<td>USF</td>
<td>Upstream stimulatory factor</td>
</tr>
<tr>
<td>UV</td>
<td>Ultraviolet</td>
</tr>
<tr>
<td>v/v</td>
<td>Volume to volume</td>
</tr>
<tr>
<td>Symbol</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------</td>
</tr>
<tr>
<td>w/v</td>
<td>Weight to volume</td>
</tr>
<tr>
<td>X</td>
<td>Times</td>
</tr>
<tr>
<td>x g</td>
<td>Fold gravity</td>
</tr>
</tbody>
</table>
ABSTRAK

pengawalaturan transkripsi gen $ck\beta$, beberapa mutasi telah diperkenalkan pada tapak pelekanan ETS dan GATA di dalam promoter $ck\beta$. Aktiviti promoter bagi binaan mutan didapati telah meningkat secara mendadak. Seterusnya, sel-sel MCF-7 yang ditransfeksikan dengan vektor pelapor promoter $ck\beta$ telah dirawat dengan forbol 12-myristat 13-asetat (PMA) untuk meninjau peranan PMA dalam mengawal tur ekspresi gen $ck\beta$ melalui factor-faktor transkripsi ETS dan GATA. PMA merupakan pengaktif PKC. Pengaktifan PKC telah meningkatkan pengawalaturan negatif, ETS dan GATA dan akhirnya mengurangkan aktiviti transkripsi promoter $ck\beta$. Keputusan menunjukkan bahawa aktiviti promoter $ck\beta$ telah dikurangkan dengan ketara selepas dirawat dengan PMA. Oleh itu, kajian ini telah mengenal pasti bahawa faktor transkripsi ETS dan GATA merupakan represor yang penting dalam pengawalaturan transkripsi gen $ck\beta$. 
CLONING AND PROMOTER ANALYSIS OF HUMAN CHOLINE KINASE ISOFORMS

ABSTRACT

Choline kinase (CK) is the first enzyme in the CDP-choline pathway for the synthesis of phosphatidylcholine in all animal tissues. CK phosphorylates choline into phosphocholine in the presence of ATP and Mg$^{2+}$. In humans, this enzyme is encoded by two separate genes, $cka$ and $ck\beta$ which produce at least three protein isoforms known as CKα1, CKα2 and CKβ. CK plays an important role in phospholipid synthesis, carcinogenesis and muscular dystrophy as well as bone deformities. The CK promoter region plays a significant role in the regulation of the $ck$ gene expression. This study reports the cloning of $cka$ and $ck\beta$ promoters and the use of a reporter system for evaluating the promoter activity. Promoter sequences of human $cka$ (2009 bp) and $ck\beta$ (2000 bp), located upstream of their respective genes, were cloned into a promoterless luciferase reporter vector, pGL4.10[luc2]. The recombinant plasmid was co-transfected with Renilla luciferase internal control vector, pGL4.73[hRLuc/SV40] into the human breast adenocarcinoma, MCF-7, cell line. Its promoter activity was measured using the luciferase assay. Various 5’-terminal deletion mutants were constructed by PCR technique and cloned into pGL4.10[luc2] vector in order to identify the region of the $cka$ and $ck\beta$ promoters that are important for gene transcription. The results showed that the ETS transcription factor is a crucial negative regulator for the $cka$ promoter while ETS and GATA transcription factors are important negative regulators for the $ck\beta$ promoter activity. To confirm the importance of ETS and GATA on the regulation of $ck\beta$ gene transcription, several mutations were introduced to the ETS and GATA
binding sites in \(ck\beta\) promoter. The promoter activities of the mutant constructs were dramatically increased. Subsequently, MCF-7 cells transfected with \(ck\beta\) promoter reporter vector were treated with phorbol 12-myristate 13-acetate (PMA) to explore the role of PMA in \(ck\beta\) gene regulation via ETS and GATA transcription factors. PMA is the activator of PKC. The activation of PKC increases the binding of negative regulators, ETS and GATA and hence decreases the transcriptional activity of \(ck\beta\) promoter. Results showed that the activity of the \(ck\beta\) promoter was significantly reduced after treatment with PMA. Thus, this study has identified ETS and GATA transcription factors as the important repressors in the regulation of \(ck\beta\) gene transcription.
CHAPTER 1.0 INTRODUCTION

1.1 Structures and functions of phospholipids

Phospholipids are the major structural components of membranes (Figure 1.1) (Campbell and Reece, 2002). In almost all cells, the structure is a phospholipid bilayer that surrounds and contains the cytoplasm (Silhavy et al., 2010). Phospholipids have only two fatty acid tails and the third hydroxyl group of glycerol is joined to a phosphate group and a simple organic molecule such as choline (Campbell and Reece, 2002). All phospholipids have hydrophobic and hydrophilic domains. The hydrophobic domain is composed largely of the hydrocarbon chains of fatty acids; the hydrophilic domain, called a polar head group, contains phosphate and other charged or polar group (McKee and McKee, 2003). Furthermore, several phospholipids are emulsifying agents and surface active agents (Kuroki and Voelker, 1994) as they are amphipathic molecules (Metzler and Metzler, 2001). Phospholipids consist of two major types: phosphoglycerides (also known as glycerophospholipids) and sphingomyelins (also known as sphingolipids) (Newsholme and Leech, 2010).

1.1.1 Phosphoglycerides

Phosphoglycerides, which are derived from glycerol, are the most abundant types of phospholipids found in cell membrane. All phosphoglycerides are derived from sn-glycerol-3-phosphate (L-Glycerol 3-phosphate). Two fatty acid chains are esteried to the first and second carbons of the glycerol molecule, denoted as positions C-1 and C-2, respectively. Saturated fatty acids normally occur at C-1 of glycerol while the fatty acid substituent at C-2 is normally unsaturated. The C-3 hydroxyl group of the glycerol backbone is esterified to form different phosphoglycerides.
Figure 1.1 The structure of plasma membrane. It is made up of phospholipid bilayer and proteins with different functions are embedded inside it (Henderson et al., 1990).
The phosphoglycerides are named and classified according to the hydroxyl is esterified to the phosphate group of the phosphatidate. Phosphatidate have four common subtituents, serine, ethanolamine, choline and inositol (Lodish et al., 2000; Berg et al., 2002; McKee and McKee, 2003; Plopper, 2011). The major classes of phosphoglycerides are shown in Table 1.1.

1.1.1(a) Phosphatidic acid

Phosphatidic acid (PA) is the simplest phosphoglyceride, it is also known as 1,2-diacyl-sn-glycerol-3-phosphate. PA is progressively being recognized as a crucial lipid second messenger in animal systems as well as in plants (Munnik, 2001; Testerink et al., 2004). Hydrolysis of PA by the enzyme phosphatidate phosphatase yields diacylglycerols, which are the precursors for the biosynthesis of triglycerides, phosphatidylcholine and phosphatidylethanolamine via the Kennedy pathway (Athenstaedt and Daum, 1999; Kooijman et al., 2005). PA also has significant roles in cell signaling and metabolic regulation in all organisms. Surprisingly, recent findings have demonstrated that PA also has an unprecedented role as a pH biosensor by coupling changes in pH to intracellular signaling pathways (Young et al., 2010; Shin and Loewen, 2011). Several proteins, including protein kinase C and small G-proteins are activated by this diacylglycerol (Yang and Kazanietz, 2007).
Table 1.1  Major types of phosphoglycerides (McKee and McKee, 2003)

<table>
<thead>
<tr>
<th>Name of X-OH</th>
<th>Formula of X</th>
<th>Name of Phospholipid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>—H</td>
<td>Phosphatidic acid</td>
</tr>
<tr>
<td>Choline</td>
<td>—CH$_2$CH$_2$N(CH$_3$)$_3$</td>
<td>Phosphatidylcholine (lecithin)</td>
</tr>
<tr>
<td>Ethanolamine</td>
<td>—CH$_2$CH$_2$NH$_3$</td>
<td>Phosphatidylethanolamine (cephalin)</td>
</tr>
<tr>
<td>Serine</td>
<td>—CH$_2$CH$\text{COO}^-$</td>
<td>Phosphatidylserine</td>
</tr>
<tr>
<td>Glycerol</td>
<td>—CH$_2$CHCH$_2$OH</td>
<td>Phosphatidylglycerol</td>
</tr>
<tr>
<td>Phosphatidylglycerol</td>
<td></td>
<td>Diphosphatidylglycerol (cardiolipin)</td>
</tr>
<tr>
<td>Inositol</td>
<td></td>
<td>Phosphatidylinositol</td>
</tr>
</tbody>
</table>
1.1.1(b) Phosphatidylcholine

Phosphatidylcholine (PC) (also known as lecithin) has choline bonded with phosphate group of the phosphatidate (Scholfield, 1981). The PC generally is the most abundant phospholipid class in a membrane, in both animal and plant. It amounts to almost 50% of the total constituents and is the key building block of membrane bilayers. Many prokaryotes lack PC, but it is estimated that more than 10% of bacteria possess PC (Sohlenkamp et al., 2003). In animal tissues, PC tends to exist mainly in the diacyl form. In mammals, it is well known that PC is found in lipoproteins, biliary lipid aggregates and lung surfactant (Kanno et al., 2007). PC is synthesized through two distinct enzymatic pathways, namely, the de novo CDP-choline pathway and the methylation pathway (Walkey et al., 1998). The CDP-choline pathway involves the conversion of choline to CDP-choline through a phosphorylcholine intermediate for condensation with diacylglycerol to produce PC. This enzymatic pathway is present in all cells. In the methylation pathway, PC is produced via sequential methylation of phophatidylethanolamine by phosphatidylethanolamine N-methyltransferase, which is expressed only in the liver cells (Fernandez-Murray and McMaster, 2005; Witola and Ben Mamoun, 2007).

1.1.1(c) Phosphatidylethanolamine

Phosphatidylethanolamine (PE) (also referred as cephalin), is the second most abundant phospholipid in animal and plant, and constitutes for more than 50% of the total phospholipid species in eukaryotic membranes (Gibellini and Smith, 2010). 20% of phospholipids in the liver are PE and as much as 45% in the brain. Higher proportions of PE are found in mitochondria than in other organelles (Vance, 2008). Besides being the major constituent of membrane, the PE is a zwitterionic
phospholipid that involves in a number of biological events, such as in the blood coagulation, blood pressure regulation, and in the visual process (Song et al., 2012). The PE is synthesized via the de novo CDP-ethanolamine pathway in which the final reaction occurs on the endoplasmic reticulum and nuclear envelope (Vance and Vance, 2009).

1.1.1(d) Phosphatidylserine

Phosphatidylserine (PS) (1,2-diacyl-sn-glycero-3-phospho-L-serine) (Gaus et al., 2005) is a quantitatively minor membrane phospholipid that makes up to 10% of the total phospholipids of mammalian cell membranes (Yamaji-Hasegawa and Tsujimoto, 2006). The cytoplasmic leaflet of the plasma membrane is generally rich in PS (Kay and Grinstein, 2011). Any disruption on the asymmetric distribution of phospholipids will lead to the appearance of PS on the cell surface. The PS is known to play a central role in both apoptosis and blood coagulation (Chaurio et al., 2009). Furthermore, PS is a required cofactor for protein kinase C (Vance and Steenbergen, 2005).

1.1.1(e) Phosphatidylglycerol

Phosphatidylglycerol (PG) is a ubiquitous lipid in biological membranes (Sakurai et al., 2007). The PG is found in bacteria, such as E.coli, which made up to 20% in bacterial membranes. It is also mainly presents in thylakoid membranes of chloroplasts, which perform specific roles in the photosynthetic process in cyanobacteria and higher plants (Henin et al., 2009; Wada and Murata, 2009). The PG is synthesized only in the mitochondria of non-photosynthetic eukaryotes such as Saccharomyces cerevisiae and it is used as a precursor for the biosynthesis of
cardiolipin (Hagio et al., 2002). The PG is the major end product of the Kennedy pathway. PG forms the bilayer of the inner membrane and the inner leaflet of the outer membrane (Lu et al., 2011). The PG is crucial for viability of wild-type cells not only because it is a major component of the inner membrane but it also plays important roles in the initiation of DNA replication of oriC and SecA-dependent protein translocation (Dowhan, 2009).

1.1.1(f) Diphosphatidylglycerol
Diphosphatidylglycerol (also known as cardiolipin, CL) is located and synthesized in the mitochondrial inner membrane (Schlame et al., 2000). It is exclusively present in membranes of bacteria and of mitochondria of eukaryotes, and hence is found in virtually all organisms of the three domains of life: eubacteria, archaebacteria and eukaryote (Schlame, 2008). Furthermore, CL is most abundantly found in human tissues especially those that are rich in mitochondria, such as heart, skeletal muscle and liver tissue (Lu et al., 2006). The CL interacts with a large number of mitochondrial proteins and effects functional activation of certain enzymes, especially those involve in oxidative phosphorylation and photo-phosphorylation that result in ATP production (Chen et al., 2006).

1.1.1(g) Phosphatidylinositol
Phosphatidylinositol (PI) can be phosphorylated to form phosphoinositide. PI participates in essential metabolic processes in animals through a number of metabolites (Kim et al., 2010). Phosphorylation of PI by a number of different kinases produces phosphatidylinositol 4-phosphate (PIP) and phosphatidylinositol 4,5-biphosphate (PIP2). The PIP2 is a substrate for phospholipase C which lead to the
production of inositol 1,4,5-triphosphate and diacylglycerol that serve as signaling molecules in animals. Inositol 1,4,5-triphosphate binds to specific receptors and induces the release of calcium from intracellular stores, while diacylglycerol activates protein kinase C, which in turn controls many key cellular functions, including differentiation, proliferation, metabolism and apoptosis (Desrivieres et al., 1998). The PI is synthesized from the phosphatidate and the reaction involves CTP to produce CDP-diacylglycerol which then combines with myo-inositol to form PI and CMP (Berridge and Fain, 1979).

1.1.2 Sphingolipids

Sphingolipid (also known as sphingomyelin) molecules consist of a long-chain amino alcohol (Figure 1.2). In animals, this alcohol is known as sphingosine (Chaurio et al., 2009). The sphingolipid is different from phosphoglycerides because it does not contain glycerol backbone although they are similar in shape (Lodish et al., 2000). The core of each type of sphingolipid is ceramide, contain a fatty acid linked by an amide bond derivative of sphingosine (McKee and McKee, 2003). A sphingomyelin is formed by the esterification of a phosphorylcholine or a phosphoethanolamine to the 1-hydroxyl group of a ceramide (McKee and McKee, 2003; Gibellini and Smith, 2010). Sphingosine-1-phosphate is a bioactive lipid and served as the primary precursor of ceramides which are involved as mediators of cellular events, for example cytoskeleton rearrangements, growth, motility and survival (Spiegel and Milstien, 2003). The ceramides are also precursors for the glycolipids (also referred to as glycosphingolipids) with an immense range of function in tissues (McKee and McKee, 2003). Furthermore, sphingomyelin and other sphingolipids together with cholesterol are located in an intimate association in
Figure 1.2  Core structure of sphingolipids, long chain bases form the core structure of sphingolipids (Rao and Acharya, 2008).
specific sub-domains to form lipid rafts, which appear to be associated with cellular signaling and the signal transduction process (Dowhan, 2009).

1.2 Biosynthesis of major phospholipids in eukaryotic membranes

The molecular basis for phospholipid function on eukaryotic systems is more complex and difficult than in prokaryotes. It is essential to study the roles of phospholipids in cell physiology and specific cellular processes (Dowhan, 1997). The studies for pathway of the major eukaryotic phospholipid biosynthesis were established mainly by Eugene Kennedy (Kennedy, 1957). Besides the study on the components of the cell membrane, the implication of phospholipid metabolites and derivatives in different mitogenic signaling pathways has also been identified (Gallego-Ortega et al., 2009). Figure 1.3 shows the pathways for the biosynthesis of major eukaryotic membrane phospholipids.
Figure 1.3 Pathways for the biosynthesis of major eukaryotic membrane phospholipids (Kent and Carman, 1999). Enzymes involved in individual steps are circled. CDP-choline pathway is shown in blue. PEMT pathway is shown in red. PLD and EK reactions are shown in black. PI and CL reactions are shown in green.

CK, choline kinase; EK, ethanolamine kinase; CCT, choline phosphate cytidylyltransferase; ECT, ethanolamine phosphate cytidylyltransferase; CPT, choline phosphotransferase; EPT, ethanolamine phosphotransferase; GPAT, glycerol-3-phosphate acyltransferase; 1 acyl-GPAT, 1 acyltransferase-GPAT; PAC, phosphatidate cytidyltransferase; PSS, phosphatidylserine synthase; PSD, phosphatidylserine decarboxylase; PEMT, phosphatidylethanolamine methyltransferase; PLD, phospholipase D; PIS, phosphatidylinositol synthase; PG-P synthase, phosphatidyglycerol phosphate synthase; PG-P phosphatase, phosphatidyglycerol phosphate phosphatase; CL synthase, cardiolipin or diphosphatidylglycerol synthase; PA, phosphatidic acid; PS, phosphatidylserine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PME, phosphatidylmonooethanolamine; PDE, phosphatidyl(diethanolamine); PI, phosphatidylinositol; PG, phosphatidylglycerol; CL, cardiolipin (diphosphatidylglycerol); CTP, Phosphocholine cytidylyltransferase; DAG, diacylglycerol; AdoMet, S-adenosylmethionine; AdoHcy, adenosylhomocysteine.
1.2.1 Synthesis of phosphatidic acid

The synthesis of PA started with the acylation of glycerol-3-phosphate. The PA biosynthesis plays an important step in the activation of fatty acids by acyl-CoA synthetase to yield acyl-CoA. Five different forms of acyl-CoA synthetase have been identified. The synthetases function differently in the biosynthesis of phospholipid and triacylglycerol (TG) (Vance and Vance, 2002). The PA can be further hydrolyzed to the central liponucleotide intermediate, cytidine diphosphate-diacylglycerol (CDP-DAG) via phosphatidate cytidyltransferase (PAC) (Figure 1.3), which is also known as CDP-DAG synthase (CDS) (Nigou and Besra, 2002). The CDP-DAG is a key intermediate in phospholipid synthesis in all organisms because of its location at the branchpoint of the biosynthetic pathway (Icho et al., 1985). The CDP-DAG plays a role as the donor of phosphatidyl moieties to the primary hydroxyl groups of serine or glycerol-3-phosphate in the generation of PI (Zuker, 1996) or CL (Sandoval-Calderon et al., 2009), respectively (Figure 1.3).

1.2.2 Synthesis of phosphatidylcholine

The PC biosynthesis consists of two pathways, the CDP-choline pathway (Kennedy pathway) and the phosphatidylethanolamine methylation (PEMT) pathway (Aoyama et al., 2004). The PEMT pathway predominates in yeast and fungi. For mammals, PEMT is significant only in mammalian liver cells for ~ 30% of hepatic PC biosynthesis while the CDP-choline pathway is the major route in other mammalian cells (Lopez-Lara and Geiger, 2001; Li and Vance, 2008).

PC can be found in significant amounts in membranes of rather diverse bacteria especially in symbionts, pathogens and photosynthetic bacteria (Sohlenkamp et al.,
2003; Comerci et al., 2006). The PC is constantly turned over to yield free choline and PA. This process is catalyzed by PLD, and the latter can be further hydrolyzed to DAG by the action of PA phosphatase (shown in black in Figure 1.3) (Kent and Carman, 1999; Zhou et al., 2000).

1.2.2(a) CDP-choline pathway

The CDP-choline pathway (shown in blue in Figure 1.3) is also known as Kennedy pathway, named after Eugene Kennedy who elucidated it in 1956 (Gibellini and Smith, 2010). The choline is mainly used for the synthesis of PC through the CDP-choline pathway, which accounts for up to 95% of the total choline pool in most tissues. The remaining 5% include free choline, phosphocholine, glycerophosphocholine, CDP-choline and acetylcholine (Li and Vance, 2008). There are three reactions involved in the CDP-choline pathway. Free choline is first catalyzed by an enzyme choline kinase (CK), and is the first reaction of choline phosphorylation by ATP (Ishidate, 1997). The second reaction is the phosphocholine cytidylyltransferase (CCT) catalyzes the formation of CDP-choline from phosphocholine and CTP (Kent, 1997). The third reaction is that cholinephosphotransferase (CPT) catalyzes the final condensation reaction of CDP-choline with diacylglycerol (McMaster and Bell, 1997; Vance and Vance, 2002).

For the CDP-choline pathway in mammals, CK activity is the first step in biosynthesis, but the CCT is considered as the regulatory as well as the rate limiting step (Lykidis and Jackowski, 2001). However, several reports have indicated that the step of CK is also slow and can be a regulatory step for the net biosynthesis of PC in certain situations (Aoyama et al., 2004). The PC biosynthesis is also required for
normal very low-density lipoprotein secretion from hepatocytes. When choline supply is deficient, recent studies indicate that choline is recycled into the liver and redistributed from the kidneys, lungs (where saturated PC is an essential lipid component of the pulmonary surfactant), and intestines to the liver and the brain (Li and Vance, 2008). However, choline itself is not synthesized \textit{de novo} in animal cells and must be obtained from dietary sources or by degradation of existing choline-containing lipids (Ishidate, 1997).

1.2.2(b) Phosphatidylethanolamine methylolation pathway

Phosphatidylethanolamine methylation (PEMT) pathway is another pathway from which PC can be synthesized \textit{de novo} in mammalian cells (shown in red in Figure 1.3). In mammalian cells, phospholipid N-methyltransferase catalyzes the three successive AdoMet-dependent methylations of phosphatidylethanolamine (Figure 1.3) (Watkins \textit{et al.}, 2003; Verkade \textit{et al.}, 2007). The PE used in the PEMT pathway is derived from PS (Kent and Carman, 1999). The PEMT is only expressed in significant levels in the liver and testis (Jackowski and Fagone, 2005).

1.2.3 Synthesis of phosphatidylethanolamine

The major pathway for the biosynthesis of PE in mammals is known to be a CDP-ethanolamine pathway (Lykidis and Jackowski, 2001) which was first described by Kennedy and Weiss in 1956 (Vance and Vance, 2002). The CDP-ethanolamine pathway consists of three enzymatic steps (Figure 1.3). Firstly, ethanolamine kinase (EK) catalyzes the ATP-dependent phosphorylation of ethanolamine, forming phosphoethanolamine and the byproduct ADP. In the second step which is considered to be the rate-limiting step of the Kennedy pathway, it is the CTP:
phosphoethanolamine cytidylyltransferase (ECT) uses phosphoethanolamine and CTP to form the high-energy donor CDP-ethanolamine with the release of pyrophosphate (Leonardi et al., 2009). The final step is catalyzed by CDP-ethanolamine: 1, 2-diacylglycerol ethanolaminephosphotransferase (EPT) using CDP-ethanolamine and a lipid anchor such as diacylglycerol (DAG) or alkylacylglycerol (AAG) to form PE and CMP as byproducts (Bleijerveld et al., 2004).

Another crucial route to synthesize PE is the decarboxylation of PS, which is described by Borkenhagen and colleagues (Bleijerveld et al., 2007). In this pathway, PS synthesized from PC or PE by phosphatidylserine-1 and -2, respectively, is decarboxylated by phosphatidylserine decarboxylase (PSD) to generate PE (Vance and Vance, 2004). To date, only one mammalian PSD has been cloned, and it was shown to be active in mitochondria (Vermeulen et al., 1997; Bleijerveld et al., 2007).

1.2.4 Synthesis of phosphatidylserine

PS is made in prokaryotes, some plants and in yeasts through the CDP-diacylglycerol pathway. However this pathway does not exist in mammalian cells. Instead, PS is synthesized by a base-exchange reaction, in which the head group of a PC or PE is exchanged for L-serine (Vance and Vance, 2002; Moldave, 2003). This pathway was first described by Hubscher in 1959 (Vance and Vance, 2002). The PS is synthesized by two distinct PS synthases, PS synthase-1 (PSS1) and PS synthase-2 (PSS2) (Arikketh et al., 2008). The PSS1 exchanges serine for the choline head group of PC, while PSS2 uses PE as a substrate (Vance and Steenbergen, 2005).
1.3 Choline kinase

Dietary choline is an essential nutrient which is absorbed by the intestine in the form of lysophosphatidylcholine and choline, and, the uptake by the cell is carried out either by passive diffusion or diffusion facilitated by specific choline transporters (Michel et al., 2006; Li and Vance, 2008). Upon entry into the cell, the choline is immediately phosphorylated to phosphocholine or oxidized to betaine. These processes take place mainly in hepatocytes (Katz-Brull et al., 2002). The phosphorylation of choline is catalyzed by choline kinase (CK) which constitutes the first step of Kennedy pathway (Ishidate, 1997).

The enzymatic reaction of CK in Brewer’s yeast was first described by Wittenberg and Kornberg in 1953 (Wittenberg and Kornberg, 1953). In human, CK (ATP: choline phosphotransferase, EC 2.7.1.32) (Aoyama et al., 2000) is encoded by two separate genes, CKA and CKB, located on chromosomes 11q13.2 and 23q13.33, respectively (Gallego-Ortega et al., 2011). Alternative splicing of the CKA transcript results in two functional isoforms, CKα1 and CKα2; CKB encodes CKβ (Wu and Vance, 2010). CKα1 has 457 amino acids while CKα2 has 439 amino acids. They are only different in an additional stretch of 18 amino acids that begin at the position 155. CKβ has 395 amino acids and its sequence is approximately 40% different from CKα1 and CKα2 (Gallego-Ortega et al., 2011). Active CK has been proposed to consist of either homo- or hetero-dimeric (oligomeric) forms, and neither isoform is active in its monomeric form (Liao et al., 2006).

Nowadays, different cDNAs of CK from yeasts, mammals and plants have been cloned and characterized (Strausberg et al., 2002; Kent, 2005). The CK also carries
the Ethanolamine Kinase activity in several organisms and has been reported to be involved in the synthesis of PE using ethanolamine as substrate to produce phosphoethanolamine (Aoyama et al., 2000; Gallego-Ortega et al., 2011). Furthermore, CK is a vital protein that involves in cancer, and the specific interference with the CK activity constitutes a new efficient strategy for cancer treatment (Ramirez de Molina et al., 2004b).

In mammals, the CK cDNA was first obtained from a rat liver λgt11 library by screening using the antibody against rat liver CK. The open reading frame encoded 435 amino acids with a molecular mass of 49743 Da (Uchida and Yamashita, 1992). Later, the liver enzyme was found to exist in two isozymes, termed CKRI and CKRII (Porter and Kent, 1990). The 5’ region of the CKR gene exhibited the features of not only a housekeeping gene but also of a gene regulated via a variety of putative cis-acting elements (Uchida, 1994).

1.3.1 Biochemical characteristic of choline kinase isoforms

Recently, the enzymatic properties of CKα1 and CKβ have been characterized in vitro and in vivo (Gallego-Ortega et al., 2011). In vitro, the Michaelis constant (Km) of CKβ for choline was higher than CKα1 while the Km of CKβ for ethanolamine was lower than CKα1. In vivo, CKβ showed only an EK role while CKα1 displayed both CK/EK roles, suggesting that each CK isoform plays distinct role in biochemical pathways under in vivo conditions and behave differently in vitro (Gallego-Ortega et al., 2009; Gallego-Ortega et al., 2011).
Homozygosity for the mutant CKα mice are lethal in embryonic stage (Wu et al., 2008) whereas mice with a knocked-out CKβ are viable to the adult stage but causes rostrocaudal muscular dystrophy (rmd) and bone deformities (Sher et al., 2006; Wu et al., 2009; Wu et al., 2010). The rmd mice show normal PC levels in all tissues except in skeletal muscle of the forelimbs with an unusual rostral-to-caudal gradient (Sher et al., 2006). The heterozygous mutant of CKα mice appeared normal in embryonic development and gross anatomy and was fertile (Wu et al., 2008). It suggests that CKα plays a crucial role under physiological conditions but CKβ is insufficient to compensate the PC biosynthesis or even to provide the minimal requirements of phosphocholine (Gallego-Ortega et al., 2011). In addition, heterozygous CKα knockout mice showed decreased PE levels (Wu et al., 2008). This suggests that there is a dual role for the CKα isoform in the biosynthesis of PC and PE (Gallego-Ortega et al., 2011).

In humans, disruption of PC synthesis by loss of function due to mutation of CKβ activity in muscle causes congenital muscular dystrophy (CMD) (Mitsuhashi et al., 2011a; Mitsuhashi et al., 2011b). The feature of the muscle pathology in humans and mice is characterized by distinct mitochondrial morphological abnormalities where mitochondria were absent in the center of muscle fibers and significantly enlarged at the periphery (Sher et al., 2006; Wu et al., 2010; Mitsuhashi et al., 2011a). PC levels are significantly decreased and CK activity is absent in the skeletal muscle from CMD human and rmd mice. However, in other tissues, where there was only a mild decrease in CK activity, PC levels are not altered and there are no obvious pathological changes. This is supported by the fact that CKα was not detected in muscle (Mitsuhashi et al., 2011b). Furthermore, loss of function through mutation of
CKβ causes mitochondria to be abnormally large and exhibit decreased inner membrane potential in hindlimb muscle of mice whereas presence of mega mitochondria was in insignificant amounts in forelimb muscle and functioned normally. Hence, the distinction in forelimb versus hindlimb muscle of CKβ deficient mice is predominantly due to CKα, but less contribution of CKβ, to total CK activity in forelimb muscle (Wu et al., 2010).

1.4 Choline kinase in cell transformation and carcinogenesis

Overexpression of CK, which leads to higher level of phosphocholine can potentially lead to carcinogenesis. CK is suggested to be involved in the ras signaling pathway mediated by the ras oncogene (Ramirez de Molina et al., 2004b). There are two well known ras oncogene effectors, PI3K and Ral-GDS (Ramirez de Molina et al., 2002a). Several ras oncogenes such as src, raf and mos could also increase the endogenous CK activity and phosphocholine level when expressed in the murine fibroblasts (Ratnam and Kent, 1995; Hernandez-Alcoceba et al., 1997; Ramirez de Molina et al., 2001).

Production of phosphocholine also plays an essential role in cell growth that are induced by growth factors both in murine fibroblasts (Kiss and Chung, 1996) and in different human cells. Treatment of human cells with growth factors such as EGF, PDGF or HRG results in blockage of DNA synthesis. The increase in growth factors induced the production of phosphorylcholine (Ramirez de Molina et al., 2004a).

Interestingly, the elevated phosphocholine levels appear to be a common characteristic feature in cell lines derived from human tumors (Bhakoo et al., 1996).
The elevation of phosphocholine level which is associated to cell malignancy is
detected by nuclear magnetic resonance (NMR). It has been demonstrated that
different tumors in murine and human, showed increased levels of phosphocholine
compared to their corresponding normal tissues (Podo et al., 2007). Phosphocholine
as a malignancy marker, such as a biomarker for breast cancer, is useful for the
diagnostic and monitoring of the cancer’s progression (Eliyahu et al., 2007).

CK generates phosphocholine in the carcinogenic process and it has been found that
CK activity was increased in tissues from human tumors (Glunde et al., 2005; Eliyahu et al., 2007; Iorio et al., 2010). Human CK, expressed in murine fibroblast,
increases DNA synthesis when stimulated by insulin, insulin-like growth factor I
(IGF-I) and other growth factors (Chung et al., 2000). The overexpression of CK in
primary human mammary epithelial cells was sufficient for growth factor-induced
proliferation because its overexpression causes an increase in DNA synthesis
(Ramirez de Molina et al., 2004a). Furthermore, high levels of CK mRNA have been
detected in colon cancer induced by 1,2-dimethylhydrazine (DMH) in rats
(Nakagami et al., 1999a) as well as in tumors induced by polycyclic aromatic
hydrocarbons (PAHs) (Mordukhovich et al., 2010). Besides, carbon tetrachloride
(CCl₄) was also induced CK activity 2–4 fold (Aoyama et al., 2002).

Most of the studies have reported that CKα is overexpressed in a variety of cell lines
derived from human tumors such as in breast, prostate, colon, brain, lung, bladder
and cervix carcinoma tumor tissues (Banez-Coronel et al., 2008; Nimmagadda et al.,
2009; Shah et al., 2010) but there is no evidence that reports overexpression of CKβ
in the carcinogenesis process (Gallego-Ortega et al., 2009). The induction of CKα
activity in these types of cancer ranges from 40% to 60% (Gallego-Ortega et al., 2006). Furthermore, a study using 167 tumor samples showed that non-small cell lung cancer (NSCLC) patients with an overexpression of CKα had a worse survival rate compared to those who did not, and this could entail important clinical consequences (Ramirez de Molina et al., 2007). Recently, overexpression of CKα1 has been shown to increase invasiveness in human breast cancer as well as resistance to treatment with 5-fluorouracil (5-FU) (Shah et al., 2010).

Recently, the implication of CKβ in cell transformation and human carcinogenesis both in vitro and in vivo has been discovered. However, the effect of CKβ overexpression on cell transformation is still not very clear. Overexpression of CKβ had no significant effect on the number or the size of the cancer cell colonies. In addition, CKβ was unable to induce tumor growth under conditions where CKα1 does (Ramirez de Molina et al., 2005; Gallego-Ortega et al., 2009).

In gene expression profiling, mRNA of CKα1 shows significant overexpression in a panel of breast, lung and ovarian cancer cell lines when compared with their normal counterparts whereas no changes were found for CKβ mRNA levels (Eliyahu et al., 2007; Gallego-Ortega et al., 2009; Iorio et al., 2010). These findings are important as the overexpression of CKα1 activity is able to transform cells from different origins (Ramirez de Molina et al., 2005; Gallego-Ortega et al., 2009; Gallego-Ortega et al., 2011). Most of the findings suggest that CKα is involved in the cell growth regulation and is altered during the carcinogenic process, hence development of new families of anticancer drugs to inhibit CKα activity may provide a novel cancer therapeutic strategy (Aoyama et al., 2004).
1.5 Promoter

A promoter is a DNA sequence which is directly upstream to the coding sequence that regulates transcription of a gene. Gene transcription is regulated by the binding of transcription factors specifically to the regions of the promoter (Xuan et al., 2005). Promoters are the best-characterized transcriptional regulatory sequences in complex genomes because of their predictable location upstream of transcriptional start site (TSS). Promoters consist of two separate segments, the core (proximal) and the extended (distal) regions.

The core promoter is normally located within 50 bp of the TSS, where the preinitiation complex forms and the general transcription machinery assembles (Cooper et al., 2006). The core promoter elements appear to interact directly with the RNA polymerase II, which is essential to begin the transcription. Most of the studies of the basal machinery have been performed with promoters that consist of the TATA box as an essential element (Smale and Kadonaga, 2003). However, the specific regulatory sequences that control spatial and temporal expression of the downstream gene are present in the extended (distal) promoter. Since promoters consist of many classes of eukaryotic transcriptional regulatory elements, hence identification and characterization of these elements are important to understand the complex network of human gene regulation (Cooper et al., 2006).

1.5.1 Transcription factors

A transcription factor is a protein which acts by binding to a specific short DNA sequence that in turn regulates the gene transcription either positively or negatively (Latchman, 1997). Transcription factors are important for the regulation of gene
expression. Transcription factors are found in all living organisms and the number of transcription factors present within an organism increases with the genome size (van Nimwegen, 2003). In the human genome, there are approximately 2600 proteins that contain DNA binding domains and most of these are presumed to function as transcription factors (Babu et al., 2004).

The transcription of a gene is regulated by trans-acting protein factors that interact with specific cis-acting elements (Schwemmle et al., 1997). Transcription of an eukaryotic protein-coding gene is preceded by several events, such as locus decondensation, remodeling of the nucleosome, histone modifications, the binding of transcriptional activators and coactivators to enhancers, and recruitment of the basal transcription machinery to the core promoter (Smale and Kadonaga, 2003). However, only a few nucleotides are significant in its function within a promoter (Baliga, 2001).

Eukaryotic transcription factors can be categorized into various families on the basis of conserved sequences among their DNA-binding domains (Table 1.2). Several distinct trans-acting factors normally interact with a common binding site due to such structural conservation. Furthermore, some findings indicate that the interaction of distinct transcription factors with a common target site does not essentially result in similar transcriptional responses. Hence, some factors may activate the transcription,
<table>
<thead>
<tr>
<th>Family</th>
<th>Representative transcription factors</th>
<th>Some functions</th>
</tr>
</thead>
<tbody>
<tr>
<td>basic leucine zipper (bZIP)</td>
<td>AP-1, CREB (Chamolstad et al., 2004; Cai et al., 2008)</td>
<td>Liver differentiation, fat cell specification (Gilbert, 2000)</td>
</tr>
<tr>
<td>basic helix-loop-helix (bHLH)</td>
<td>SRY, AhR/Ar, USF (Luo and Sawadogo, 1996; Bhandari et al., 2011; Pocar et al., 2005)</td>
<td>Sex-determination, carcinogenesis (Ledent and Vervoort, 2001; Gilbert, 2000)</td>
</tr>
<tr>
<td>zinc finger</td>
<td>GATA, MZF1, Sp1, Ik</td>
<td>Carcinogenesis, expressed in hematopoietic progenitors including erythroid cells (Gaboli et al., 2001; Viger et al., 2008; Deniaud et al., 2006; Dijon et al., 2008)</td>
</tr>
<tr>
<td>Rel homology</td>
<td>NF-kappa</td>
<td>Human diseases (Ahn and Aggarwal, 2005)</td>
</tr>
<tr>
<td>winged helix-turn-helix (wHTH)</td>
<td>E2F, ETS, HSF, Elk-1</td>
<td>Carcinogenesis, response to various stresses, (Donaldson et al., 1996; Hashikawa et al., 2006)</td>
</tr>
<tr>
<td>grainyhead-related protein</td>
<td>CP2 (To et al., 2010)</td>
<td>Erythroid gene expression (Kokoszynska et al., 2008)</td>
</tr>
</tbody>
</table>